| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
IQ3 selectively targets the c-Jun N-terminal kinase (JNK) family, with its primary target being JNK3. It exhibits Kd values of 66 nM for JNK3, 240 nM for JNK1, and 290 nM for JNK2. The compound shows selectivity for JNKs over a panel of 131 other kinases at a concentration of 10 µM, highlighting its specificity for the JNK pathway. By inhibiting JNK3, IQ3 modulates downstream signaling pathways involved in cellular stress responses and inflammation.
|
|---|---|
| ln Vitro |
The IC50 values of IQ-3 are 2.2 μM (TNF-α in human monoMac-6 cells), 1.5 μM (IL-6 in human monoMac-6 cells), 4.7 μM (TNF-α in human PBMC), 9.1 μM (IL-6). 6) in human PBMC and 6.1 μM (NO in mouse J774.A1) respectively [1]. IQ-3 suppresses LPS-induced NF-κB/AP-1 transcriptional activity in human THP-1 Blue monocytes with an IC50 of 1.4 μM [1]. IQ-3 is certainly a competitive inhibitor of the JNK3 ATP binding site [1].
IQ3 demonstrates potent in vitro activity as a JNK inhibitor, with a Kd of 66 nM for JNK3. It inhibits LPS-induced NF-κB/AP1 transcriptional activity in THP1-Blue cells with an IC50 of 1.4 μM. Furthermore, IQ3 inhibits the production of the pro-inflammatory cytokines TNF-α and IL-6 in vitro. These findings indicate that IQ3 effectively blocks JNK-mediated signaling and inflammatory responses in cellular models. |
| ln Vivo |
In vivo activity data for IQ3 is limited in the provided references. As a potent JNK3 inhibitor with an IC50 of 1.4 µM for inhibiting NF-κB/AP1 transcriptional activity in cell-based assays, IQ3 is expected to exhibit in vivo efficacy in animal models of inflammation and cancer where JNK signaling is a key driver. Its oral bioavailability is not specified, but its use as a research tool suggests potential for in vivo applications in preclinical studies.
|
| Enzyme Assay |
The primary in vitro enzyme assay for IQ3 involves measuring its binding affinity (Kd) to JNK1, JNK2, and JNK3 using a competition binding assay. This cell-free system typically uses purified recombinant JNK proteins and a labeled tracer to quantify the compound's ability to displace the tracer, thereby determining its Kd value. The assay is performed in a buffer system optimized for kinase binding, and the results confirm the compound's selectivity for JNK3 over other JNK isoforms.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: PBMC. Tested Concentrations: 0-80 μM (200 ng/mL LPS). Incubation Duration: 30 minutes. Experimental Results: TNF-α concentration was downregulated (IC50 = 4.7 μM). In vitro cellular assays for IQ3 involve treating THP1-Blue cells, which are a reporter cell line for NF-κB/AP1 activity, with the compound. Cells are stimulated with LPS to induce NF-κB/AP1 transcriptional activity, and the inhibitory effect of IQ3 is measured by quantifying the reporter gene signal. The IC50 of 1.4 µM is determined from dose-response curves. Additionally, the compound's effect on TNF-α and IL-6 production can be measured in culture supernatants by ELISA. |
| Animal Protocol |
In vivo animal experiments for IQ3 are not detailed in the provided references. However, as a JNK inhibitor, IQ3 could be evaluated in standard animal models of inflammation, such as the LPS-induced sepsis model or models of autoimmune diseases, to assess its efficacy in reducing inflammatory markers and tissue damage. Its pharmacokinetic properties would need to be characterized for such studies.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for IQ3, such as oral bioavailability, half-life, and tissue distribution, is not provided in the referenced sources. The compound is a small molecule with a molecular weight of 341.32 g/mol and a molecular formula of C20H11N3O3. It is soluble in DMSO, with a solubility of 5 mg/mL (14.64 mM), which is typical for compounds used in in vitro and in vivo research applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for IQ3 is not detailed in the provided sources. As a research compound, it is not intended for human use and is supplied for laboratory research purposes only. Standard safety precautions should be followed when handling this compound. Its safety profile would need to be established through preclinical studies if it were to be developed for therapeutic applications.
|
| References | |
| Additional Infomation |
IQ3 is a specific c-Jun N-terminal kinase (JNK) inhibitor that exhibits a preference for JNK3, with Kd values of 66 nM for JNK3, 240 nM for JNK1, and 290 nM for JNK2. It is a valuable research tool for studying the JNK signaling pathway, particularly in the context of inflammation and cancer. The compound's selectivity for JNKs over a panel of 131 kinases highlights its specificity. IQ3 is available from various chemical suppliers for research purposes only.
|
| Molecular Formula |
C20H11N3O3
|
|---|---|
| Molecular Weight |
341.32
|
| Exact Mass |
341.08
|
| CAS # |
312538-03-7
|
| PubChem CID |
6877540
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.812
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
26
|
| Complexity |
581
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C\2C(=C1)C3=NC4=CC=CC=C4N=C3/C2=N\OC(=O)C5=CC=CO5
|
| InChi Key |
WBSWWONMTZEOGS-NKFKGCMQSA-N
|
| InChi Code |
InChI=1S/C20H11N3O3/c24-20(16-10-5-11-25-16)26-23-18-13-7-2-1-6-12(13)17-19(18)22-15-9-4-3-8-14(15)21-17/h1-11H/b23-18-
|
| Chemical Name |
[(Z)-indeno[1,2-b]quinoxalin-11-ylideneamino] furan-2-carboxylate
|
| Synonyms |
IQ 3 IQ-3 IQ3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~73.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9298 mL | 14.6490 mL | 29.2980 mL | |
| 5 mM | 0.5860 mL | 2.9298 mL | 5.8596 mL | |
| 10 mM | 0.2930 mL | 1.4649 mL | 2.9298 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
